key: cord-0993635-2pu70kby
authors: Ganesan, Govindaraj; Ponniah, Sasipriya; Sundaram, Vivek; Kumar Marimuthu, Praveen; Pitchaikannu, Venkatraman; Chandrasekaran, Manigandan; Thangarasu, Janakiraman; Kannupaiyan, Gunasekaran; Ramamoorthy, Prabhu; Thangaraj, Brindha; Shree Vaishnavi, Raguram
title: Response to Comments on “Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India”
date: 2021-12-08
journal: Radiother Oncol
DOI: 10.1016/j.radonc.2021.12.001
sha: 3ba480c4c25bbc1011702ac9d97f3e97f0123f3b
doc_id: 993635
cord_uid: 2pu70kby

nan

We have gone through the comments put forward by Ghaznavi et al 1 andfirstly, we sincerely thank the authors and appreciate their interest in our manuscript. 2 Their first concern is about the use of corticosteroids for all patients included in our study. We would like to clarify that, as stated in the manuscript's inclusion criteria point 1, pharmacological therapy was based on the then guidelines of Indian Ministry of Health and family welfare for the management of moderate to severe COVID-19.Remdesivir, Zinc and Ascorbic acid were excluded from the treatment guidelines later following emergence of new evidence. Secondly, the authors have commented that 'patients requiring oxygen were not clearly described/identified in the study'. All patients required and received supplemental oxygen as they met the criteria defined in inclusion criteria point 2.

Lastly, about the duration of follow-up, we do agree that 2 weeks follow-up was not ideal, especially for mortality data and mentioned the same ourselves in the manuscript as one of the limitations of the study.

Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India

Whole lung irradiation as a novel treatment for COVID-19: Interim results of an ongoing phase 2 trial in India